GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomised placebo-controlled phase 2 trial (COVITAR)

·      GRAd-COV2 vaccine based on a recently developed group C gorilla adenoviral vector

·      Phase 2 trial confirms favorable safety profile for single and double dose regimens

·      SARS-CoV-2 binding/neutralizing Ab boosted by homologous or heterologous vaccine

·      Potent, VOC cross-reactive, functional and durable CD4 and CD8 T cell responses